Literature DB >> 32949600

Selegiline and clomipramine effects on lymphocyte subsets, regulatory T cells and sheep red blood cell (SRBC)-induced humoral immune response after in vivo administration in mice.

Marianna Szczypka1, Anna Sobieszczańska2, Agnieszka Suszko-Pawłowska3, Magdalena Lis4.   

Abstract

We aimed at investigating the influence of clomipramine and selegiline administered in vivo in mice on lymphocyte subsets in lymphoid organs and SRBC-induced humoral immune response. Balb/c mice were given 7 or 14 oral doses (1 mg/kg) of selegiline or clomipramine. Lymphocyte B and T subsets and splenic regulatory T cell (Treg) subset were determined in non-immunized mice 24 and 72 h after the last dose of the drugs. Some mice treated with 7 doses were immunized with sheep red blood cells (SRBC) 2 h after the last dose, and their number of antibody forming cells, haemagglutinin titers and splenocyte subsets were determined. An increase in T lymphocytes and a decrease in B cells were visible in peripheral lymphoid organs, especially after 14 doses of selegiline or clomipramine in non-immunized mice, as well as in spleens of SRBC-immunized mice. The most pronounced change was a decrease in CD4+/CD8+ ratio resulting mainly from an increase in CD8+ subset after seven doses of the drugs in the non-immunized mice. However, it was of a transient nature, as it disappeared after 14 doses of the drugs. The tested drugs only slightly affected thymocyte maturation and did not alter Treg subset. Selegiline and clomipramine transiently stimulated IgG production in SRBC-immunized mice. Both selegiline and clomipramine administered in vivo modulated lymphocyte subsets. This immunomodulatory effect depended on the drug as well as duration of administration.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clomipramine; Lymphocyte subsets; Regulatory T cells; SRBC-Induced immune response; Selegiline

Mesh:

Substances:

Year:  2020        PMID: 32949600     DOI: 10.1016/j.ejphar.2020.173560

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Specific immune status in Parkinson's disease at different ages of onset.

Authors:  Jun Tian; Shao-Bing Dai; Si-Si Jiang; Wen-Yi Yang; Yi-Qun Yan; Zhi-Hao Lin; Jia-Xian Dong; Yi Liu; Ran Zheng; Ying Chen; Bao-Rong Zhang; Jia-Li Pu
Journal:  NPJ Parkinsons Dis       Date:  2022-01-10

2.  Effect of giving probiotic supplement Lactobacillus acidophilus La-14 as an immunomodulator to maintain a respiratory system in Mus musculus.

Authors:  Dita Artanti; Yeti Eka Sispita Sari; Fitrotin Azizah; Nur Vita Puwaningsih; Vella Rohmayani; Dede Nasrullah
Journal:  Iran J Microbiol       Date:  2021-06

3.  Molecular Mechanism Exploration of Autologous Blood Transfusion with RBC Surface Membrane Protein pMHC/aCD28 Combined with CD8+T Cells to Promote the Proliferation of CD8+T Cells to Inhibit the Malignant Transformation of Liver Cancer.

Authors:  Haiyong Tao; Tong Liu; Na Yao; Jinhuo Wang; Jiaming Xu; Xiaofang Zhou; Xiaofei Chen; Jianrong Guo
Journal:  J Oncol       Date:  2022-09-28       Impact factor: 4.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.